- Home
- WOW vs ENGN Comparison
WOW vs ENGN Comparison
Compare WOW & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOW
- ENGN
- Stock Information
- Founded
- WOW 2001
- ENGN 1999
- Country
- WOW United States
- ENGN Canada
- Employees
- WOW N/A
- ENGN N/A
- Industry
- WOW Cable & Other Pay Television Services
- ENGN
- Sector
- WOW Telecommunications
- ENGN
- Exchange
- WOW Nasdaq
- ENGN Nasdaq
- Market Cap
- WOW 440.8M
- ENGN 379.3M
- IPO Year
- WOW 2017
- ENGN N/A
- Fundamental
- Price
- WOW $5.18
- ENGN $7.66
- Analyst Decision
- WOW Hold
- ENGN Buy
- Analyst Count
- WOW 2
- ENGN 8
- Target Price
- WOW $5.20
- ENGN $22.75
- AVG Volume (30 Days)
- WOW 376.1K
- ENGN 3.3M
- Earning Date
- WOW 11-05-2025
- ENGN 12-18-2025
- Dividend Yield
- WOW N/A
- ENGN N/A
- EPS Growth
- WOW N/A
- ENGN N/A
- EPS
- WOW N/A
- ENGN N/A
- Revenue
- WOW $590,800,000.00
- ENGN N/A
- Revenue This Year
- WOW N/A
- ENGN N/A
- Revenue Next Year
- WOW N/A
- ENGN N/A
- P/E Ratio
- WOW N/A
- ENGN N/A
- Revenue Growth
- WOW N/A
- ENGN N/A
- 52 Week Low
- WOW $3.06
- ENGN $2.65
- 52 Week High
- WOW $5.48
- ENGN $11.14
- Technical
- Relative Strength Index (RSI)
- WOW 59.57
- ENGN 51.77
- Support Level
- WOW $5.15
- ENGN $6.31
- Resistance Level
- WOW $5.20
- ENGN $11.14
- Average True Range (ATR)
- WOW 0.02
- ENGN 0.94
- MACD
- WOW -0.00
- ENGN -0.03
- Stochastic Oscillator
- WOW 71.43
- ENGN 34.50
About WOW WideOpenWest Inc.
WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.